Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tagrisso Funding Journey Shows UK’s Revamped Cancer Drugs Fund Is No Soft Touch

Executive Summary

AstraZeneca’s Tagrisso is the first product accepted for use on the National Health Service through the reformed Cancer Drugs Fund, but it took two tries to persuade HTA body NICE it should be funded at all. NICE examined Merck Sharp & Dohme’s Keytruda and it’s not impressed. The Pink Sheet takes a closer look at the new dynamics illustrated by these lung cancer treatments’ review.

You may also be interested in...



UK NICE Says Yes To Vizimpro & Libtayo But Rejects Tagrisso

Pfizer and AstraZeneca were seeking National Health Service funding for the same indication for their respective lung cancer drugs. With "responsible pricing" after an initial rejection, Pfizer prevailed.

Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.

Positive Tagrisso Data Boost AstraZeneca's Lung Cancer Ambitions

Latest data from AstraZeneca's Tagrisso will help the company to convert the lung cancer drug's conditional approvals to full approvals, and boost reimbursement negotiations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel